TDENV LAV

Drug Profile

TDENV LAV

Alternative Names: Dengue vaccine live - GlaxoSmithKline; T-DEN F-19; T-DEN F17; TDENV-LAV F17; Tetravalent dengue live attenuated virus formulation 17; WRAIR Live Attenuated Tetravalent Dengue Vaccine

Latest Information Update: 18 Jun 2013

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Oswaldo Cruz Foundation; Walter Reed Army Institute of Research
  • Class Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dengue

Most Recent Events

  • 18 Jun 2013 Discontinued - Phase-II for Dengue (prevention, in children) in Puerto Rico (SC)
  • 18 Jun 2013 Discontinued for Dengue in Brazil (SC)
  • 18 Jun 2013 Discontinued - Phase-II for Dengue (prevention, in adults) in Puerto Rico (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top